Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734771 · ClinicalTrials.gov registry record · Phase 2

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Patrick Reagan.

Active
Registry status
Phase 2
Development phase
24
Enrollment target
2
Study locations

NCT02734771 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Patrick Reagan. The registered enrollment target is 24 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734771, a Phase 2 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Patrick Reagan.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab vedotin.

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Rituximab
  • DRUG Prednisone
  • DRUG Brentuximab vedotin

Study Locations (2)

New York

  • James P. Wilmot Cancer Institute, University of Rochester Medical Center - Rochester

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-06
Est. Completion 2025-12
Phase Phase 2

Sponsor

Patrick Reagan

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02734771

The ClinicalTrials.gov registry entry for NCT02734771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is Patrick Reagan, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT02734771 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Virginia.

Frequently Asked Questions

What is clinical trial NCT02734771 about?

NCT02734771 is a clinical study titled "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)". This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab ...

What is the current status of trial NCT02734771?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-06. Estimated completion is 2025-12.

What conditions does trial NCT02734771 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT02734771?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Prednisone (DRUG), Brentuximab vedotin (DRUG).

Who is sponsoring clinical trial NCT02734771?

This trial is sponsored by Patrick Reagan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02734771 being conducted?

This trial has 2 study locations across New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.